Furthermore, rodent studies have implicated TRM cells in anti-tumour immunity, by showing that mice lacking CD69 or CD103 or other TRM-associated molecules (e.g., CD49a) are more susceptible to transplanted B16 melanoma (182–184). This evidence concerns the gene ITGAE and neoplasm.